VNDA

4.85

0.62% 0.03

Handel nachbörslich: 4.86 0.01 +0.21%

Vanda Pharmaceuticals Inc (VNDA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.82

Offen:

$4.83

24-Stunden-Volumen:

455.32K

Relative Volume:

0.72

Marktkapitalisierung:

$282.79M

Einnahmen:

$192.64M

Nettoeinkommen (Verlust:

$2.51M

KGV:

92.56

EPS:

0.0524

Netto-Cashflow:

$12.42M

1W Leistung:

+0.83%

1M Leistung:

-1.22%

6M Leistung:

-9.51%

1J Leistung:

+13.32%

1-Tages-Spanne:

$4.79

$4.9038

1-Wochen-Bereich:

$4.7105

$4.955

52-Wochen-Spanne:

$3.46

$6.75

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Firmenname

Vanda Pharmaceuticals Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (669)

Telefon

202-734-3400

Adresse

2200 PENNSYLVANIA AVE NW, WASHINGTON

Mitarbeiter

203

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

VNDA's Discussions on Twitter

Vergleichen Sie VNDA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VNDA Vanda Pharmaceuticals Inc	4.85	282.79M	192.64M	2.51M	12.42M	0.0524
VRTX Vertex Pharmaceuticals Inc	407.11	104.84B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	718.15	78.92B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	621.29	37.15B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	234.28	30.22B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.79	27.76B	3.30B	-501.07M	1.03B	-2.1146

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-31	Eingeleitet	H.C. Wainwright	Buy
2024-07-11	Eingeleitet	Cantor Fitzgerald	Overweight
2022-02-25	Herabstufung	Jefferies	Buy → Hold
2021-05-12	Eingeleitet	BofA Securities	Buy
2021-01-14	Herabstufung	Citigroup	Buy → Neutral
2020-10-29	Hochstufung	Citigroup	Neutral → Buy
2020-06-09	Herabstufung	Citigroup	Buy → Neutral
2020-03-16	Herabstufung	Oppenheimer	Perform → Underperform
2020-03-12	Hochstufung	Citigroup	Neutral → Buy
2019-11-07	Herabstufung	Citigroup	Buy → Neutral
2019-08-01	Hochstufung	Citigroup	Neutral → Buy
2019-07-25	Herabstufung	Stifel	Buy → Hold
2018-12-11	Herabstufung	Oppenheimer	Outperform → Perform
2018-12-04	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2018-12-04	Bestätigt	Jefferies	Buy
2018-11-08	Fortgesetzt	Jefferies	Buy
2018-09-21	Fortgesetzt	Oppenheimer	Outperform
2018-05-23	Eingeleitet	Citigroup	Buy
2018-01-19	Eingeleitet	Seaport Global Securities	Buy
2017-09-14	Bestätigt	Piper Jaffray	Overweight
2017-06-27	Fortgesetzt	Piper Jaffray	Overweight
2017-05-26	Eingeleitet	H.C. Wainwright	Buy
2017-04-12	Eingeleitet	Oppenheimer	Outperform
2016-11-09	Eingeleitet	Aegis Capital	Buy
2016-10-06	Fortgesetzt	Jefferies	Buy

Alle ansehen

Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten

Dec 27, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Dec 27, 2024

Dec 24, 2024

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance

Dec 24, 2024

Dec 23, 2024

Vanda’s VGT-1849A gets orphan designation for polycythemia vera - BioWorld Online

Dec 23, 2024

HC Wainwright Reiterates Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Dec 23, 2024

Dec 20, 2024

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity - Seeking Alpha

Dec 20, 2024

Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment - MarketWatch

Dec 20, 2024

Exploring Three High Growth Tech Stocks In The United States - Simply Wall St

Dec 20, 2024

Vanda Pharmaceuticals Secures FDA Orphan Drug Status for Novel Blood Cancer Treatment VGT-1849A - StockTitan

Dec 20, 2024

Dec 19, 2024

Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail

Dec 19, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat

Dec 19, 2024

Dec 18, 2024

FDA's Gastro Drug Fast-Track Denial Survives DC Circ. - Law360

Dec 18, 2024

US Penny Stocks To Watch In December 2024 - Simply Wall St

Dec 18, 2024

Dec 17, 2024

DC Circuit Affirms FDA's Fast-Track Denial of Vanda Stomach Drug - Bloomberg Law

Dec 17, 2024

Dec 16, 2024

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc. - Marketscreener.com

Dec 16, 2024

Dec 14, 2024

Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com

Dec 14, 2024

Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Dec 14, 2024

Dec 11, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat

Dec 11, 2024

Dec 10, 2024

Vanda Expands Efforts to Pull Two Hetlioz Copies From US Shelves - Bloomberg Law

Dec 10, 2024

Dec 01, 2024

Vanda Pharmaceuticals (STU:VM4) EV-to-Revenue : -0.37 (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Nov 28, 2024

Massachusetts Financial Services Co. MA Purchases New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Nov 28, 2024

Nov 26, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve

Nov 26, 2024

Nov 19, 2024

Long Term Trading Analysis for (VNDA) - Stock Traders Daily

Nov 19, 2024

Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com Canada

Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India

Nov 18, 2024

Nov 14, 2024

New Strong Buy Stocks For November 14th - Barchart

Nov 14, 2024

Nov 12, 2024

Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan

Nov 12, 2024

BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Nov 12, 2024

Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India

Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia

Nov 08, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 07, 2024